German Federal Joint Committee recognises added benefit of once-daily LIXIANA® (edoxaban) for preventing stroke and syst

1) Gemeinsamer Bundesausschuss - G-BA. Tragende Gründe. zum Beschluss des Gemeinsamen

Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII -

Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach

Section 35a SGB V - Edoxaban. January 2016.

2) SMC Advice Directory. Edoxaban (LIXIANA). Available at:

https://www.scottishmedicines.org.uk/SMC...

doxaban_Lixiana_NVAF. (Last accessed January 2016).

3) Daiichi Sankyo press release - UK's NICE recommends once-daily LIXIANA(R) (edoxaban)

for preventing stroke and systemic embolism in patients with non-valvular atrial

fibrillation. 24 September 2015. Available at:

http://www.daiichisankyo.com/media_inves...

354.html. (Last accessed January 2016).

4) Daiichi Sankyo press release - Daiichi Sankyo's Once-Daily Lixiana(R) (edoxaban)

Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial

Fibrillation and for the Treatment and Prevention of Recurrent Venous Thromboembolism

in Switzerland. 15 April 2015. Available at:

http://www.daiichisankyo.com/media_inves...

269.html. (Last accessed January 2016).

5) Zorginstituut Nederland. GVS-rapport 15/12 edoxaban (Lixiana(R)) bij

atriumfibrilleren. 8 September 2015.

6) Giugliano R, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N

Engl J Med. 2013;369(22):2093-2104.

7) Camm A, et al. Guidelines for the management of atrial fibrillation: the Task Force

for the Management of Atrial Fibrillation of the European Society of Cardiology

(ESC). Eur Heart J. 2010;31(19):2369-429.

8) Allender S, Scarborough P, Peto V, et al. European Cardiovascular Disease Statistics

2012 Edition.

EDX 16 0026 January 2016 

Contact 

Lydia Worms (Europe) 

Daiichi Sankyo Europe GmbH 

Edoxaban Communications & Product PR Europe 

+49(89)7808751